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Abstract: The enzyme, arginase, converts L-arginine into L-ornithine and urea, and has been implicated in the 
pathogenesis of lung diseases, related to dysregulation of L-arginine metabolism and remodeling. Allergic asthma is a 
chronic condition characterized by inflammation, lung remodeling and airways hyperresponsiveness (AHR). Increased 
expression of arginase may contribute to AHR in asthma by reducing L-arginine bioavailability for the nitric oxide 
synthase (NOS) isozymes, thus, limiting the production of the endogenous bronchodilator, nitric oxide (NO). Reduction of 
intracellular L-arginine concentrations as a consequence of augmented arginase expression and activity may also promote 
NOS uncoupling, resulting in increased formation of peroxynitrite, a powerful oxidant that promotes bronchoconstriction 
and inflammation. In chronic asthma, increased arginase expression may also contribute to airways remodeling, through 
increased synthesis of L-ornithine, and hence the production of polyamines and L-proline, which are involved in cell 
proliferation and collagen deposition, respectively. New drugs targeting the arginase pathway could have therapeutic 
benefits in asthma. This review focuses on recent developments in our understanding of the role of arginase in AHR, 
inflammation and remodeling, highlighting studies that advance our knowledge of L-arginine dysregulation in human 
asthma and animal studies that explore the therapeutic potential of arginase inhibition. 
Keywords: Nitric oxide, L-arginine, airways remodeling, inflammation, airway hyperresponsiveness, polyamines, fibrosis, 
proline, peroxynitrite. 
INTRODUCTION 
 The metabolism of the semi-essential amino acid L-
arginine has been of great interest since the Nobel Prize 
winning research programs of Furchgott, Ignarro and Murad, 
which led to the discovery of nitric oxide (NO) as a bioactive 
molecule. For many years, the catabolism of L-arginine to 
NO and L-citrulline was considered the most important 
biologically active pathway. In recent years, however, 
metabolism of L-arginine to urea and ornithine via the 
arginase family of isozymes has emerged as an important 
pathway in numerous physiological and pathophysiological 
conditions, including lung disease. 
SUMMARY OF REVIEWS TO DATE 
 Reflecting the increased interest in arginase, there have 
been several recent reviews describing the role in lung 
disease and immunology. Maarsingh et al. recently described 
the therapeutic potential of arginase inhibition in asthma [1]. 
A review by Meurs et al. focused on the airways 
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animal models of variable and chronic AHR [2]. The role of 
arginase in the regulation of airway smooth muscle tone by  
the nervous system was also described, along with the role of 
arginase in the chronic structural changes and remodeling of 
airway smooth muscle in AHR [2]. Maarsingh et al. 
reviewed the current knowledge of arginase induction in a 
variety of pulmonary diseases including asthma, COPD, 
cystic fibrosis, pulmonary hypertension, and remodeling and 
fibrotic disorders [3]. The unifying role of arginase in these 
diseases of the lung was the regulation of the synthesis of 
NO, polyamines and L-proline [3], contributing to smooth 
muscle reactivity, tissue hypertrophy/hyperplasia and 
collagen deposition, respectively. In another review from 
2008, Maarsingh et al. reviewed the importance of altered L-
arginine metabolism in AHR, inflammation and remodeling 
in allergic asthma, focusing on the three mechanisms that 
regulate L-arginine bioavailability within the cell: uptake, 
catabolism and recycling from L-citrulline [4]. In 2007, 
Peranzoni et al. reviewed the potential roles of L-arginine 
metabolism in the early and late immune response to 
inflammatory insults and in the pathology of a variety of 
neoplastic and autoimmune diseases [5]. Mori reviewed the 
regulation of apoptosis by the balance of nitric oxide 
synthesis through arginase and L-arginine recycling through 
L-citrulline [6]. Morris also reviewed the current state of 
knowledge about L-arginine metabolism in 2007, including 
transport into the cell and mitochondria and its 
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interconversion from and into different amino acids as well 
as the multiple products of different pathways of L-arginine 
catabolism [7]. The interested reader is directed to these 
comprehensive reviews. The aim of the current review is to 
unify the recent advances in our knowledge of arginase in 
asthma, specifically focusing on the in vivo inhibitory 
studies, and reports that translate L-arginine metabolism via 
arginase to human asthma. 
NITRIC OXIDE HOMEOSTASIS AND AIRWAY 
FUNCTION 
 NO is synthesized from L-arginine in a 2-step reaction 
with N

-hydroxy-L-arginine (NOHA) as an intermediate by a 
family of NO-synthases that utilize oxygen and NAPDH as 
cosubstrates and yield L-citrulline as a coproduct [8,9]. Three 
NOS isoforms that are expressed from three distinct gene 
products have been identified: neuronal NOS (nNOS or NOS 
I) and endothelial NOS (eNOS or NOS III), which are 
constitutively expressed, and inducible NOS (iNOS or NOS 
II). In the airways, the constitutive NOS (cNOS) isozymes 
are mainly expressed in airway epithelium (NOS1 and 
NOS3), inhibitory nonadrenergic noncholinergic (iNANC) 
neurons (NOS1), and in endothelial cells from the airway 
vasculature (NOS3). cNOS isoforms produce relatively low 
levels of NO in response to increases in intracellular Ca
2+
, 
evoked by membrane depolarization or by contractile 
agonists [10]. The activity of NOS2, which produces large 
amounts of NO, is regulated at the expressional level, e.g. by 
proinflammatory cytokines during airway inflammation [10-
12]. 
 NO is an important endogenous bronchodilator, inducing 
airway smooth muscle relaxation via mechanisms that are 
both dependent and independent of cGMP, generated 
through activation of soluble guanylyl cyclase by NO, 





-sensitivity, and membrane 
hyperpolarization of the smooth muscle cell [10]. The 
bioavailability of L-arginine for the NOS isozymes 
determines the formation of NO in the airways, as illustrated 
by the finding that in healthy subjects the levels of exhaled 
NO are increased by oral or inhalational administration of L-
arginine [13-15]. In guinea pig airway preparations in vitro, 
L-arginine diminishes airway constriction by methacholine 
[16], and increases iNANC nerve-mediated smooth muscle 
relaxation [17], as a consequence of increased formation of 
cNOS-derived NO. 
 In many cells, the availability of L-arginine for the NOS 
isozymes depends on L-arginine uptake by the cell through 
specific cationic amino acid transporters (CATs), recycling 
of L-citrulline to L-arginine, and on the activity of arginase 
which competes with NOS for the common substrate [4]. 
Uptake of L-arginine via the Na
+
-independent CATs of the 
y
+
- system (Fig. 1), the major transcellular L-arginine 
transporter [18], can be inhibited by other cationic amino 
acids such as L-ornithine and L-lysine, as well as by 
polycations, including major basic protein (MBP) from 
eosinophils [19]. Thus, MBP and its analogue poly-L-
arginine attenuates L-arginine uptake and NO-synthesis in 
alveolar macrophages and tracheal epithelial cells [19], and 
increases airway responsiveness of rats and guinea pigs to 
methacholine, in vivo and in vitro [20,21] by inducing a 
deficiency of NO [21]. The L-arginine availability may also 
be regulated by recycling of the NOS-product L-citrulline, 
through the L-citrulline/L-arginine cycle [22,23]. This cycle 
consists of the enzymes L-argininosuccinate synthase and L-
argininosuccinate-lyase (ASS and ASL, respectively), which, 
in various tissues, are colocalized and coinduced with NOS 
isozymes [23-27]. Although recycling of L-citrulline does 
not play a role in iNANC NO-mediated relaxations of human 
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conditions, the inhibitory effect of the NOS-inhibitor N

-
nitro-L-arginine was reversed by L-citrulline [28,29], which 
was prevented by ASS and ASL inhibitors, indicating that 
the L-citrulline/L-arginine cycle is effective under conditions 
of low L-arginine utilization by NOS1 [29]. For a detailed 
review on the role of L-arginine transport and L-citrulline 
recycling in regulating airway function in health and disease 
see: [4]. 
 The third and most studied mechanism that regulates the 
L-arginine availability to NOS is substrate competition by 
arginase, which converts the amino acid into L-ornithine and 
urea [4,30], and will be the focus of the current review. 
Although the Km of L-arginine for arginase is up to 1000-fold 
higher than for NOS, substrate competition can occur, 
because the Vmax is also 1000-fold higher [30-32]. Two 
isozymes, arginase 1 and arginase 2, encoded by different 
genes, have been identified [30,33,34]. Arginase 1 is the 
major isozyme in the liver and is involved in the urea cycle, 
whereas arginase 2 is predominantly expressed 
extrahepatically [30,35,36]. In the airways, both isozymes 
are constitutively present in structural cells, including the 
epithelium, endothelium, (myo)fibroblasts and airway 
smooth muscle cells [37-40], as well as in inflammatory 
cells, such as alveolar macrophages and neutrophils 
[36,37,41]. It is becoming increasingly appreciated that the 
cellular and sub-cellular localization of these two isozyme 
families likely contributes to their potential roles in 
homeostasis and disease pathology (this will be discussed 
later in this review). 
 The significance of arginase in regulating airway 
function is clearly demonstrated by the effects of the potent 
and specific arginase inhibitor N

-hydroxy-nor-L-arginine 
(nor-NOHA) on epithelial-derived and nerve-derived NO-
generation, even in non-diseased airways. Thus, nor-NOHA 
attenuated methacholine-induced constriction of intact 
perfused guinea pig tracheae as well as iNANC-mediated 
relaxations of isolated tracheal smooth muscle preparations 
[17,42]. These effects of nor-NOHA were quantitatively 
similar to those of L-arginine, indicating that substrate 
competition between NOS and arginase is indeed involved 
[16,17,42]. 
 However, in the non-inflamed mouse airways, inhalation 
of arginase-specific inhibitors (i.e., BEC [43] and nor-
NOHA) did not affect basal central airways or total lung 
resistance, whereas the nonspecific arginase inhibitor 
NOHA, which also acts as substrate for the NOS isozymes 
and thus increase NO levels directly, reduced baseline tone 
(North et al., unpublished observation). The ineffectiveness 
of specific arginase inhibitors is is likely a consequence of 
the low-levels of arginases expressed in normal, non-
diseased lungs [43]. Furthermore, in unrestrained guinea 
pigs, permanently instrumented with a pulmonary balloon 
catheter for on-line measurement of pleural pressure, 
inhalation of the potent and isozyme-nonselective arginase 
inhibitor 2(S)-amino-6-boronohexanoic acid (ABH) or L-
arginine did not decrease the basal responsiveness of the 
airways to histamine, measured as a 100% increase of 
pleural pressure, either [44]. Thus, it would appear that under 
normal homeostatic conditions in the airways in vivo, 
arginase and NOS do not compete significantly for L-
arginine as substrate. 
 In alveolar macrophages, arginase was found to regulate 
NO-production by NOS, and vice versa, Thus, NOS was able 
to inhibit arginase activity through NOHA, the intermediate 
product in NO synthesis [45]. The bioavailability of L-
arginine to NOS could also be regulated by the arginase 
product L-ornithine, which competitively inhibits the uptake 
of L-arginine via specific CATs of the y
+
-system [46-48]. 
Consistent with this finding, incubation with L-ornithine 
increased airway responsiveness in perfused guinea pig 
tracheal preparations by inducing a deficiency of cNOS-
derived NO [49]. Although L-ornithine also competitively 
inhibits arginase activity [32,49,50], the increase in airway 
responsiveness shows that the inhibitory effect on L-arginine 
uptake is larger than that on arginase activity [49]. Thus, 
mutual interactions between NOS and arginase regulate      
L-arginine homeostasis and NO-synthesis in the airways 
(Fig. 1) and changes in this balance may underlie the 
pathophysiology of obstructive airways diseases, including 
asthma.  
ARGINASE IN ASTHMA 
 Allergic asthma is a chronic inflammatory disorder of the 
airways that is characterized by reversible airways 
obstruction. Characteristic features of the disease are 
allergen-induced, IgE-mediated early (EAR) and late (LAR) 
asthmatic reactions, infiltration of inflammatory cells - 
particularly eosinophils and Th2 lymphocytes - into the 
airways, and inflammation-induced acute and transient 
airway hyperresponsiveness (AHR) that is present both after 
the EAR and LAR [51,52]. Chronic airway inflammation 
may induce airway remodeling, characterized by structural 
changes in the airway wall, including subepithelial fibrosis 
and increased airway smooth muscle mass [51,53,54]. 
Airway remodeling may contribute to a progressive decline 
in lung function, as well as to the development of persistent 
AHR [51,52]. The mechanisms underlying AHR are only 
partially understood. However, recent evidence suggests that 
alterations in L-arginine metabolism induced by arginase 
may be importantly involved in both acute and chronic AHR, 
via altered NO metabolism and synthesis of polyamines and 
L-proline, respectively [2,4,55]. 
Role of Altered NO Metabolism in Acute Allergen-
Induced AHR 
 In asthmatic patients, the production of NO in the 
airways is considerably increased due to marked 
upregulation of NOS2 by pro-inflammatory cytokines, such 
as tumor necrosis factor (TNF)- and IL-1 [10]. The 
increased NO production by NOS2 is associated with 
increased concentrations of NO in the exhaled air [14]. In 
experimental asthma, NOS2 is induced during the allergen-
induced LAR, similarly leading to enhanced levels of NO in 
the exhaled air [56,57]. Significant correlations between 
exhaled NO, NOS2 expression in airway epithelial and 
inflammatory cells, airway eosinophilia and AHR have been 
observed in asthmatics, whereas all are reduced after 
glucocorticosteroid treatment [58-60]. Therefore, the NO 
concentration in exhaled air is considered as a sensitive 
marker of airway inflammation in asthma [61].  
 However, many studies have indicated that airway 
inflammation is not primarily caused by high concentrations 
of NOS2-derived NO by itself, but rather by increased 
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formation of peroxynitrite (ONOO
-
), a highly reactive 
oxidant synthesized by the reaction of NO with superoxide 
anions (O2
-
) in the inflamed airways [58,62]. Thus, whereas 
NO causes bronchodilation and has anti-inflammatory 
actions by inhibiting the activation of NF-B [10,11,63-65], 
peroxynitrite has shown to induce pro-inflammatory effects 
associated with epithelial damage, eosinophil activation, 
MUC5AC expression, and vascular hyperpermeability [66-
69]. In addition, peroxynitrite promotes airway smooth 
muscle contraction [12,70]. Accordingly, increased 
nitrotyrosine immunostaining, indicative of protein tyrosine 
nitration by peroxynitrite, has been observed in airway 
epithelial and inflammatory cells of bronchial biopsies from 
asthmatic patients as well as in airways of allergen-
challenged guinea pigs [58,67]. Moreover, increased levels 
of exhaled NO correlate with increased nitrotyrosine 
concentrations in exhaled breath condensate of asthmatic 
patients [71], while nitrotyrosine staining in bronchial 
biopsies of these patients was shown to correlate with NOS2 
expression, eosinophilic airway inflammation and AHR [58]. 
In line with these observations, animal studies have indicated 
that increased formation of peroxynitrite may importantly 
contribute to the development of allergen-induced AHR after 
the LAR in acute and chronic asthma [12,62,66,70,72].  
 Remarkably, in transgenic mice overexpressing NOS2 in 
the airways, increased levels of exhaled NO were associated 
with reduced airway resistance and airway 
hyporesponsiveness, with no signs of airway inflammation 
and increased nitrotyrosine staining, indicating that increased 
production of NO per se is not detrimental, but rather 
protective [73]. Moreover, allergen-induced airway 
inflammation and AHR were more pronounced in NOS2 
knock-out mice than in wild type animals [74], although 
unchanged AHR [75] and inflammation [75,76] as well as 
reduced inflammation [77,78] have also been reported (for a 
comprehensive review on the role of NOS isoforms in 
asthma, see Mathrani et al [79]).  
 Despite the increased concentration of NO in exhaled air 
of asthmatics, various studies in animal models and in 
asthmatic patients have now indicated that acute allergen-
induced AHR is paradoxically due to a deficiency of 
bronchodilating and anti-inflammatory NO in the airway 
wall, which may be caused by a reduced L-arginine 
availability to both cNOS and NOS2 [3,4,55,80]. The first 
evidence for a role of reduced production of cNOS-derived 
NO in allergen-induced AHR came from studies in guinea 
pig models of acute allergic asthma. In these models, NOS2 
is not detected before the LAR [57], making it possible to 
investigate the distinct role of cNOS-derived NO in the EAR 
and the AHR immediately after the EAR. In an initial study, 
it was demonstrated that NO in the exhaled air drops below 
baseline during the allergen-induced EAR, which might 
contribute to the obstructive reaction as well as to the 
ensuing AHR [81]. Indeed, both in vivo and ex vivo studies 
using a guinea pig model of acute allergic asthma indicated 
that a deficiency of contractile agonist-induced cNOS-
derived NO is an important determinant of the AHR after the 
EAR [82-84]. A deficiency of cNOS activity and 
endogenous bronchodilating NO causing AHR was also 
demonstrated after repeated allergen challenges of sensitized 
guinea pigs [85]. Interestingly, a deficiency of iNANC 
nerve-derived NO was also found after single or repeated 
allergen challenges [86,87]. Ricciardolo and coworkers 
importantly demonstrated that a reduction in cNOS-derived 
NO also contributed to the AHR in patients with severe 
asthma treated with glucocorticosteroids, that inhibit the 
expression of NOS2 [88]. Moreover, as in guinea pigs, the 
deficiency of cNOS-derived NO could be induced by 
allergen challenge [89]. Interestingly, reduced cNOS- 
(presumably iNANC nerve)- derived NO could also be 
involved in attenuated deep inspiration-induced 
bronchoprotection in asthmatic patients [90-92]. 
 Animal studies further indicated that reduced L-arginine 
bioavailability to cNOS importantly accounts for the NO 
deficiency after the allergen-induced EAR (for review see 
[4]). Thus, exogenous L-arginine reduced the AHR to 
methacholine in perfused tracheal preparations of allergen-
challenged guinea pigs ex vivo [16], and increased iNANC 
nerve-mediated airway smooth muscle relaxation in tracheal 
open-ring preparations from these animals [86]. Moreover, it 
was recently demonstrated that inhalation of L-arginine 
attenuates the allergen-induced AHR to histamine after the 
EAR in guinea pigs in vivo [44]. 
 Since it has been shown that (particularly NOS3-derived) 
NO inhibits airway inflammation by suppression of NF-B 
activity, thereby inhibiting the expression of pro-
inflammatory cytokines as well as of NOS2 [63-65,93], the 
deficiency of cNOS-derived NO after the EAR could also 
contribute to the inflammatory response during the LAR. 
Accordingly, in asthmatic patients significant correlations 
were found between allergen-induced AHR after the LAR 
and reduced NOS3 expression as well as increased NOS2 
expression in bronchial biopsies [89]. Moreover, allergen-
induced airway inflammation was markedly reduced in 
NOS3-overexpressing mice as compared with wild-types 
[93,94]. Furthermore, in the acute ovalbumin sensitization 
and challenge model in mice, pulmonary NOS2 expression is 
up-regulated and NOS3 expression is down-regulated [43], 
likely further contributing to peribronchiolar inflammation in 
this model. 
 The enhanced production of peroxynitrite observed after 
the LAR could be caused by reduced L-arginine 
bioavailability to NOS2. Thus, studies in macrophages have 
indicated that under conditions of low L-arginine availability 
NOS2 not only produces NO by its oxygenase moiety, but 
also synthesizes superoxide anions by the reductase moiety, 
leading to extremely efficient formation of peroxynitrite 
[95]. Increasing the L-arginine concentration in these cells 
stimulates NO production, while reducing the production of 
superoxide anions, and hence peroxynitrite [96]. The 
potential importance of this mechanism in the AHR after the 
LAR was recently indicated by observations in a guinea pig 
model of asthma, demonstrating that administration of 
exogenous L-arginine inhibits the allergen-induced AHR 
after the LAR both ex vivo and in vivo [44,97]. 
 Since the bioavailability of L-arginine to NOS isozymes 
is regulated by arginase, increased consumption of the amino 
acid by arginase could explain the L-arginine limitation and 
subsequent AHR after the EAR and LAR in allergic asthma. 
In support of this hypothesis, the arginase activity in tracheal 
homogenates obtained from ovalbumin-challenged guinea 
pigs after the EAR was increased almost 4-fold compared to 
controls [98], whereas a 2-fold increase was observed after 
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the LAR [97]. Ovalbumin also strongly increased lung 
arginase activity in mouse [43,99,100] and rat [101] models 
of acute allergic asthma. The arginase activity in mouse lung 
was also increased after challenge with Dermatophagoides 
farinae [102], Aspergillus fumigatus [99] and trimilletic 
anhydride [100], suggesting that arginase is a key mediator 
in the response to allergic and occupational stimuli.  
 A number of studies using different mouse models of 
allergic asthma have investigated mRNA or protein 
expression of arginase 1 and 2 after allergen challenge (for 
review see [3]). Both isoforms are induced in lungs of mice 
challenged with either ovalbumin [43,99], D. farinae [102], 
A. fumigatus [99], trimilletic anhydride [100] or S. mansoni 
eggs [103], the induction of arginase 1 being the most 
prominent. Microarray analysis of gene expression in mouse 
lung after challenge with either ovalbumin or A. fumigatus 
showed that among the 291 genes that were commonly 
induced by these allergens, the genes encoding for arginase 1 
and 2 were among the most predominantly overexpressed 
[99]. Th2 cytokines, which are elevated in allergic asthma, 
seem to play an important role in the induction of arginase 1 
[99,103-105] and – to a lesser extinct – arginase 2 [99]. In 
addition, arginase 1 was among the 26 commonly expressed 
transcripts that were (strongly) increased in lung 
inflammation in 5 different mouse models of Th2 cytokine-
mediated inflammation [106]. The cytokine-induced 
expression of arginase 1 is under important control of the 
transcription factors STAT6 and CCAAT-enhancer binding 
protein [99,104,107-109], whereas the induction of arginase 
2 is largely STAT6 independent [99].  
Role of Arginase in Allergen-Induced NO Deficiency and 
Acute AHR Ex vivo 
 To study whether increased arginase activity indeed 
contributes to the reduced bioavailability of L-arginine and 
subsequent NO deficiency and AHR after the EAR, the 
effect of the specific arginase inhibitor nor-NOHA was 
studied in perfused tracheal preparations obtained from 
allergen-challenged guinea pigs [98]. Interestingly, the 
allergen-induced AHR after the EAR was completely 
inhibited by nor-NOHA to the level of normoreponsive 
unchallenged controls [98]. The effect of nor-NOHA was 
completely prevented by coincubation with the NOS 
inhibitor L-NAME, clearly demonstrating that arginase 
inhibition reduces the AHR by restoring the production of 
cNOS-derived NO [98]. Treatment with nor-NOHA also 
restored the impaired iNANC-nerve mediated NO 
production and airway smooth muscle relaxation after the 
EAR [86]. The effects of nor-NOHA were quantitively 
similar to the effect of treatment with L-arginine [86,98]. The 
importance of increased arginase in limiting the L-arginine 
bioavailability and NO production is supported by the 
observation that levels of L-arginine and L-citrulline are 
reduced in the airways of allergen-challenged mice, whereas 
the arginase activity is increased [110]. In conclusion, 
increased arginase activity underlies the deficiency of 
neuronal and nonneuronal NO and subsequent AHR after the 
EAR by limiting the substrate availability to cNOS isoforms. 
Of note, since L-arginine transport via the y
+
-system is 
inhibited by L-ornithine [46-48] leading to a deficiency of 
NO and increased airway responsiveness [49], increased 
formation of L-ornithine by arginase could also contribute to 
the L-arginine limitation and NO deficiency in allergic 
asthma. 
 As indicated above, the AHR after the LAR is caused by 
increased formation of peroxynitrite [12], due to reduced 
bioavailability of L-arginine for NOS2, which causes 
uncoupling of this enzyme [95,97]. Since the arginase 
activity in the airways of these animals is increased [97], 
increased consumption of L-arginine by arginase could by 
involved in this process. Indeed, inhibition of arginase 
reduced the AHR by restoring the production of 
bronchodilating NO, presumably by preventing the 
uncoupling of NOS2 [97]. These findings clearly indicate 
that the AHR after the LAR is caused by increased formation 
of peroxynitrite and not by an excess of NO. Increased 
arginase activity similarly underlies the peroxynitrite- 
mediated AHR in a guinea pig model of chronic asthma [72]. 
The importance of arginase in uncoupling of NOS2 and 
subsequent peroxynitrite formation is further supported by 
the observation that increased expression of arginase and 
NOS2 are colocalized with increased nitrotyrosine staining 
in lungs of D. farinae-challenged mice [102]. 
 Collectively, these functional ex vivo studies demonstrate 
that increased arginase activity contributes importantly to 
allergen-induced AHR after both the EAR and LAR by 
limiting the bioavailability of L-arginine to the NOS 
isozymes, leading to a deficiency of bronchodilating NO and 
increased formation of peroxynitrite.  
In vivo Treatment with Arginase Inhibitors 
 The effectiveness of arginase inhibition in reducing in 
vivo AHR in allergic asthma has been recently studied in 
different animal models using a number of inhibitors (Table 
1). The first report on the effect of arginase inhibitors on 
AHR in vivo was in a guinea pig model of acute allergic 
asthma, measuring airway responsiveness to inhaled 
histamine in permanently instrumented, freely moving 
animals. In these animals, treatment via inhalation with the 
specific arginase inhibitor ABH at 5.5 and 23.5 h after a 
single allergen challenge acutely reversed the AHR after the 
EAR and the LAR [44]. Using the same animal model of 
asthma, the AHR after the EAR was also acutely reduced 
after treatment with inhaled nor-NOHA (Table 1; Maarsingh 
et al., unpublished observation). Similar to the finding in 
guinea pigs, inhalation of nor-NOHA acutely reversed the 
allergen-induced AHR of the central airways to inhaled 
methacholine in an acute murine model of allergic airways 
inflammation (Table 1; North et al., unpublished 
observation). Moreover, in these mice inhalation of the 
specific arginase inhibitor S-(2-boronoethyl)-L-cysteine 
(BEC) normalized the allergen-induced AHR of the central, 
but not the peripheral, airways (Table 1) [43]. This finding 
contradicts a previous observation in mice, showing that 
oropharyngeal aspiration of BEC 2 h after the last of three 
ovalbumin challenges did not affect AHR of the central 
airways 46 h later [111]. In these animals, BEC did not 
reduce – but rather accelerated - the peak-response of the 
peripheral airways to methacholine [111]. An explanation for 
the discrepancies is currently not at hand. In addition to the 
specific arginase inhibitors ABH, BEC and nor-NOHA, 
inhaled treatment with the non-specific arginase inhibitor, 
NOHA, normalized the AHR to methacholine in a mouse 
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model of allergic asthma (Table 1; North et al., unpublished 
observation). However, NOHA is also substrate for NOS. 
Therefore, the effect of NOHA may at least partially result 
from a direct stimulation of NO synthesis, in addition to 
increasing the L-arginine availability to NOS by inhibiting 
arginase. 
 AHR to inhaled methacholine persists in a mouse model 
of chronic allergic asthma, in which the animals were 
challenged every other week for 2 consecutive days for a 
period of 12 weeks [43]. Treatment with inhaled BEC 24 h 
after the last of 12 allergen challenges completely 
normalized the AHR of the central as well as the peripheral 
airways in these mice (Table 1), clearly indicating that 
increased arginase activity also contributes to the AHR in 
vivo in chronic asthma [43]. Furthermore, in the chronic 
asthma model the isozyme responsible for the AHR appears 
to be arginase 1, since the expression of arginase 2 is not 
increased in this model [43]. 
 Distinct from the aforementioned treatment-based 
protocols, the protective effect of arginase inhibitors on 
allergen-induced AHR in asthma has also been studied in 
both guinea pigs and mice. Remarkably, the sensitivity of the 
airways to the inhaled allergen of sensitized guinea pigs was 
largely reduced after treatment with inhaled ABH 0.5 h prior 
to allergen challenge as compared to pretreatment with saline 
[44]. This anti-allergic effect of the arginase inhibitor may 
involve increased formation of NO, which is known to 
inhibit mast cell activation, as well as a number of mast cell-
Table 1. Effectiveness of Arginase Inhibitors in Reducing (Allergen-Induced) AHR In Vivo in Various Animal Models of Asthma 
 
Inhibitor Species Route Dose Inhibition of AHR Asthma Model References 
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aAssesment of AHR at 5 h (EAR) and 23 (LAR) after single allergen challenge, treatment 15 min before reassessment of AHR at 6 h and 24 h;  
btreatment 0.5 h before and 8 h after single allergen challenge, AHR assessed at 6 h (EAR) and 24 h (LAR);  
ctreatment 2 h after allergen challenge, AHR assessed at 48 h;  
dtreatment 15 min before assessment of AHR at 24 h after the last of 6 daily allergen challenges;  
etreatment 15 min before assessment of AHR at 24 h after the last of 12 allergen challenges.  
fAssesment of AHR at 5 h (EAR) after single allergen challenge, treatment 15 min before reassessment of AHR at 6 h;  
gtreatment 0.5 h before each of 6 allergen challenges, AHR assessed 1-3 h after the last challenge;  
htreatment 27 h and 24 h before IL-13 instillation, AHR assessed 12 h after IL-13 instillation;  
inebulizer concentration in an 8 L cage;  
jtotal volume of 40 μl, equals ~3 μg BEC;  
kbody weight, equals ~800 μg BEC; 
l in 100 μl PBS;  
m 25 μg of plasmid in 50 μl ExGen500 and 5% w/v glucose;  
[*], Maarsingh et al, unpublished observation;  
[**] North et al, unpublished observation. 
Abbreviations: ABH, 2(S)-aminoboronohexanoic acid; AHR, airway hyperresponsiveness; BEC, S-(2-boronoethyl)-L-cysteine; EAR, early asthmatic reaction; LAR, late asthmatic 
reaction; OVA, ovalbumin; NOHA, N-hydroxy-L-arginine; nor-NOHA, N-hydroxy-nor-L-arginine. 
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mediated inflammatory processes [112]. In addition, NO 
inhibits the allergen-induced mast cell mediator release from 
guinea pig lung parenchymal tissue [113]. When saline- and 
ABH-pretreated animals were challenged to a similar 
bronchial obstruction, thus requiring a higher allergen dose 
in the ABH-treated animals, the AHR after the EAR as well 
as after the LAR was partially reduced in the ABH-treated 
animals [44]. However, almost full inhibition of the AHR 
after the EAR and full inhibition of the AHR after the LAR 
were obtained, when the ABH-treated guinea pigs were 
challenged with the same allergen dose that induced airway 
obstruction in saline-treated animals (Table 1) [44]. The 
initial allergen-induced bronchial obstruction and the 
magnitudes of the early and late asthmatic reactions were 
also greatly reduced by pretreatment with ABH [44]. The 
protective effect of arginase inhibitors on the development of 
allergen-induced AHR was confirmed in another mouse 
model of asthma, showing that treatment with 
intraperitoneally applied nor-NOHA 0.5 h before each of 6 
allergen challenges, over the course of two weeks, 
significantly reduced the AHR to methacholine assessed 1-3 
h after the last allergen challenge (Table 1) [74]. In addition, 
treatment with interference RNA against arginase 1 
prevented the IL-13-induced upregulation of arginase 1 in 
mouse lung as well as the AHR induced by this cytokine 
[104]. In this mouse model, increased arginase 1 expression 
correlated temporally with the development, persistence, and 
resolution of IL-13-induced AHR [104]. All arginase 
inhibitors studied in the in vivo models are subtype 
nonselective and therefore the contribution of the two 
arginase isoforms to the development of allergen-induced 
AHR in these models is not known. However, whereas both 
isoforms were increased in the acute mouse model, only 
arginase 1 was upregulated in the chronic mouse model [43]. 
 In conclusion, targeting increased arginase activity using 
(inhaled) arginase inhibitors may be a novel therapeutic 
strategy in allergic asthma, since these inhibitors acutely 
reduce allergen-induced AHR, have anti-allergic properties 
and protect against the development of allergen-induced 
AHR and bronchial obstructive reactions.  
Role of Arginase in Human Asthma 
 There is increasing evidence that arginase is also 
important in the pathophysiology of human asthma [114]. 
Quite remarkably, as early as in 1980 enhanced arginase 
activity was found in sputum from asthmatic patients, which 
at that time was ascribed to disturbed liver function due to 
hypoxia [115]. It took, however, more than 20 years to 
appreciate the potential importance of this finding 
[55,98,99,114]. Increased arginase expression and/or activity 
have now also been demonstrated in airway and lung tissue, 
BAL cells and serum from asthmatic patients 
[39,43,99,114,116].  
 Increased protein and mRNA expression of arginase 1 in 
asthmatic patients was first described by Zimmerman et al. 
[99]. Northern blot analysis revealed increased mRNA 
expression of arginase 1 in inflammatory cells and airway 
epithelium in bronchial biopsies of these patients, while 
increased protein expression of the enzyme was observed in 
inflammatory cells, presumably macrophages, in the BAL. 
Accordingly, the recent study by North et al. [43] 
demonstrated increased arginase activity and protein 
expression of arginase 1, but not arginase 2, in lung tissues 
from asthmatic patients. Furthermore, immunohistochemical 
studies have indicated augmented arginase 1 protein 
expression in the airway epithelium and airway smooth 
muscle layer of smoking asthmatics compared to non-
smoking patients, which might be induced by nicotine [39].  
 Remarkably, in asthmatic patients experiencing an 
exacerbation, arginase activity in serum was considerably 
increased, whereas L-arginine levels in the plasma were 
strikingly reduced [116]. Moreover, improvement of asthma 
symptoms in some of these patients was associated with a 
decline in arginase activity and increased L-arginine 
concentrations [116]. These findings indicate that changes in 
arginase expression are not solely confined to the airways 
and that reduced levels of circulating L-arginine could 
contribute to NO deficiency in the airways. In support, in 
patients with severe asthma serum arginase activity was 
inversely correlated with FEV1 and FEV1/FVC, whereas a 
positive correlation was found between L-arginine 
bioavailability and lung function [114]. Of interest is the 
recent finding that human neutrophils contain high levels of 
arginase in azurophilic granules [41], as it is known that 
infiltration and activation of these cells in the airways is 
particularly enhanced in severe asthma. 
 In addition to the changes in expression and activity of 
arginase described above, single nucleotide polymorphisms 
(SNPs) in the arginase 1 and 2 genes have recently also been 
associated with allergic asthma. Thus, a significant 
association between SNPs in arginase 2 and increased risk of 
childhood asthma has been observed, whereas in the same 
population of children SNPs in both arginase 1 and arginase 
2 were associated with atopy [117]. Quite remarkably, 
pharmacogenetic screening of 844 SNPs in 111 candidate 
genes for association with inhaled 2-agonist-induced 
bronchodilation recently identified arginase 1 as a potential 
2-agonist response gene [118]. 
ARGINASE IN INFLAMMATION 
 Persistent inflammation plays a defining role in asthma, 
and one of the central goals of current asthma therapy is to 
minimize this process [119,120]. Inflammation and 
expression of arginase has also been demonstrated in all 
commonly-studied animal models of allergic inflammation, 
including rat, guinea pig, and mouse, as well as in human 
asthma [39,43,86,97-99,101,110]. While arginase expression 
has been found to be upregulated in epithelia, smooth muscle 
and the peribronchiolar region [39,43,99,102], this section 
will focus on new developments in our understanding of 
arginase expression and function in immune cells.  
 In 1995, Corraliza and Modolell reported the induction of 
arginase in murine macrophages by Th2 cytokines [121, 
122]. Further studies have revealed upregulation of arginase1 
by IL-4 and IL-13, through a STAT6-dependent enhancer-
mediated mechanism [109,123]. Increased arginase 1 mRNA 
expression was demonstrated in two independent murine 
models of allergic airways inflammation by Zimmermann et 
al., localized to macrophages and areas of peribronchiolar 
inflammation [99]. Arginase-positive inflammatory cells 
were also demonstrated in the mucosa of human asthmatic 
bronchial biopsy and bronchoalveolar lavage samples [99]. 
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Following these seminal findings, arginase has been found to 
be highly expressed in alternatively-activated macrophages 
[124,125], and to play an important role in allergic 
inflammation and asthma [43,100-102,104,110] . Relatively 
little information is available regarding the expression and 
function of arginase in human inflammatory cells, compared 
to murine models. This section will provide an overview of 
arginase in immune cells, as it is reviewed comprehensively 
elsewhere in this supplement. 
 Munder et al. [41] reported the first comparative 
examination of arginase expression in human and murine 
immune cells and showed that in contrast to the highly-
inducible expression of arginase that occurs in murine 
macrophages and dendritic cells, human polymorphonuclear 
leukocytes and eosinophils express arginase 1 constitutively; 
with no significant inducibility in any of the human immune 
cell populations. Arginase is sequestered within azurophilic 
granules in these cell types, and exocytosed after activation 
[41,126]. As such, the release of arginase 1 by PMNs 
contributes towards the antimicrobial/fungicidal activity 
[41], controls L-arginine concentrations in the local 
microenvironment, and supresses the activation of T-
lymphocytes [127] and natural killer cells [128]. The 
subcellular localization of arginase in PMNs has been 
challenged by Jacobsen et al., who described that arginase 1 
is localized to gelatinase granules of human PMNs, as 
opposed to the earlier-stage azurophilic granules [129]. Since 
considerable heterogeneity in infiltrating cell types can exist 
between asthmatic individuals, and since asthmatic subtypes 
with severe disease can exhibit predominantly neutrophilic 
inflammation [130-133], arginase induction within this cell 
population could likely contribute to arginine dysregulation 
in human asthma. 
 Murine macrophages are capable of inducing expression 
of arginase 1 in response to various stimuli, including Th2 
cytokines and transforming growth factor (TGF) [134]. 
Furthermore, Erdely et al. also demonstrated that arginase 1 
could be induced by IL-4 in combination with 
pharmacologic tools that increase cAMP levels (i.e., 
forskolin, which activates adenylate cyclase, and 
phosphodiesterase inhibitors) in both human alveolar 
macrophages and murine RAW264.7 cells [134]. Thus, the 
potential for arginase to play a role in arginine 
balance/imbalance in macrophages is likely dependent upon 
the cell populations studied and the conditions used for 
induction. Understanding the complex control of arginase 
expression within these cells will be important to advance 
research in allergic asthma. 
Arginase and Alternatively-Activated Macrophages 
 The primary function of classically-activated 
macrophages is the cytotoxic killing of microbes through the 
production of reactive oxygen and nitrogen species, 
including high levels of NO produced by NOS2. Classical 
activation of macrophages depends on cytokines derived 
from activated CD4
+
 T helper 1 cells (Th1), particularly 
IFN- [125]. Alternative activation of macrophages was 
proposed in the early 1990’s, as a phenotype induced by the 
Th2 cytokine IL-4 and characterized by suppression of IL-1 
synthesis and expression of the macrophage mannose 
receptor [135,136]. Alternative-activation is characterized by 
the expression of several signature proteins, including 
arginase 1, chitinase-like molecules (Ym1, Ym2 and acidic 
mammalian chitinase; AMCase), and resistin-like molecule 
(RELM, also known as FIZZ1) [124]. The cells responsible 
for producing IL-4 and initiating the alternative activation of 
macrophages include CD4
+
 Th2 cells, CD8
+
 T cells, NK 
cells, basophils, mast cells, and eosinophils, indicating that 
alternative activation can be elicited by either the innate or 
the acquired immune system [125]. Alternative-activation 
and expression of arginase 1 has been described in 
macrophages in a variety of diseases, including interstitial 
pulmonary fibrosis [137]. Arginase likely plays a detrimental 
role by limiting substrate for NOS2 in diseases in which a 
Th1 response is required. However, arginase expressed in 
alternatively-activated macrophages likely plays a role in T 
cell regulation, and the shift of L-arginine metabolism from 
NO production to the synthesis of polyamines and proline is 
likely important for the resolution of inflammation and 
wound healing [125,138,139]. Given that arginine 
metabolism via the arginase pathway leads to the production 
of polyamines and collagen, it is exciting to postulate that 
alternative activation of macrophages might contribute to the 
airway remodeling of asthma.  
Arginase Inhibition and Allergic Inflammation 
 To elucidate the role of arginase in allergic inflammation, 
recent studies have explored arginase inhibition in animal 
models. These studies, involving different animal models 
and administration protocols, have yielded conflicting 
results, with one group reporting enhancement of 
inflammation [111], two groups reporting attenuation 
[44,74], and one group reporting no effect [140]. 
Mechanisms proposed to be important in the alteration of 
inflammatory status following arginase inhibition are the 
modulation of anti-inflammatory NO, pro-inflammatory 
peroxynitrite, and subsequent effects on the transcription 
factor, NF-B.  
 In a recent study, Ckless et al. investigated the effects of 
arginase inhibition in an ovalbumin sensitization and –
challenge model of allergic airways inflammation employing 
female BALB/c mice [111]. Mice were sensitized to 
ovalbumin on days 0 and 7, and challenged for 30 min with 
aerosolized 1% ovalbumin or vehicle on days 14–16 [111]. 
The arginase inhibitor BEC was administered by 
oropharyngeal aspiration, two hours after the last challenge 
(40μl of 0.3mmol/L) and BAL and tissues were collected 46 
hours later [111]. While BEC did not affect allergen-induced 
increases in differential cell counts or cytokine levels in 
BAL samples, the authors report significant enhancement of 
peribronchiolar and perivascular inflammation based on 
semi-quantitative scoring of histological sections [111]. 
Increases in both S-nitrosothiols and 3-nitrotyrosine were 
detected, without any apparent change in nitrite/nitrate levels 
[111]. The authors also report increased DNA binding of the 
NF-B transcription factor, resulting in augmentation of 
cDNA expression for proinflammatory cytokines, neutrophil
 
attractant protein (KC) and macrophage inflammatory 
protein-3 (CCL20) [111]. The same group and others have 
previously shown that the activation of NF-B is 
redox-sensitive, activated by tyrosine nitration, but inhibited 
by S-nitrosothiols [141-143]. In lung epithelial cells the 
cytokine-induced NF-B activation was decreased following 
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arginase inhibition, with concomitantly increased 
concentrations of NO and S-nitrosothiols [144]. In another 
study, the cytokine-induced activation NF-B was decreased 
following arginase inhibition in lung epithelial cells, with 
concomitant increases in NO and s-nitrosothiols [144]. In 
addition the expression of KC and CCL20 in epithelial cells 
was attenuated by treatment with BEC [144]. Ckless et al. 
explain these apparent discrepancies by pointing to the 
possibility that increased NO produced following arginase 
inhibition may be converted into peroxynitrite [111]. While 
increased 3-nitrotyrosine was demonstrated in their study, 
S-nitrosothiols were also increased [111], making it unclear 
whether the balance lies in favour of reactive nitrogen 
species or anti-inflammatory S-nitrosothiols following 
arginase inhibition . 
 In another recently-published murine study, Bratt et al. 
demonstrated that administration of the arginase inhibitor, 
nor-NOHA (100 g i.p), or vehicle, prior to each ovalbumin 
challenge reduced the total cells in BAL fluid by 
approximately 65% [74]. The authors postulated that 
arginase inhibition shunts L-arginine substrate towards the 
NOS pathway, partially blocking the allergen-induced 
inflammation through the anti-inflammatory effects of NO 
[74]. The same group recently demonstrated that increased 
expression of arginase in isolated airways correlate with 
levels of lung inflammation [110]. Interestingly, an increased 
inflammatory response to ovalbumin was observed in NOS2 
knockout mice, supporting the anti-inflammatory effects of 
NO [74].  
 Recent studies in guinea pig models of allergen-induced 
airway inflammation also support the anti-inflammatory 
potential for arginase inhibition [44]. The arginase inhibitor 
ABH was administered by inhalation 30 minutes before and 
8 hours after allergen challenge [44]. The allergen-induced 
increases in the numbers BAL cells, including eosinophils, 
macrophages and total inflammatory cell infiltration were all 
inhibited by ABH by approximately 50% [44]. As mentioned 
above, arginase inhibitors may reduce airway inflammation 
through an increase in anti-inflammatory NO production by 
cNOS as well as reduced NF-kB activation [44,94,144]. In 
addition, inhibition of arginase may also attenuate airway 
inflammation by reducing the formation of proinflammatory 
peroxynitrite via restoring the L-arginine availability to 
NOS2, thereby preventing the uncoupling of this enzyme, 
caused by allergen-induced upregulation of arginase [97]. 
Remarkably, the sensitivity of the airways to the inhaled 
allergen was also markedly reduced in the ABH-pretreated 
guinea pigs compared to saline-pretreated animals [44].  
 A recent study investigated the role of bone marrow cell-
derived arginase 1 in the development of allergen-induced 
lung inflammation. To this aim, Niese et al. generated 
chimeric mice using irradiated CD45.1 congenic mice and 
bone marrow derived from arginase 1
-/-
 pups [140]. At 7–14 
weeks post-irradiation, the authors employed two 
independent models of experimental asthma; the ovalbumin 
model and the A. fumigatus model [140]. In developing the 
chimeric mouse, the authors found that arginase 1 deficiency 
did not affect bone marrow reconstitution, immune cell 
development or adaptive immunity, as assessed by the 
production of allergen-specific antibodies [140]. Mice that 
received arginase 1
-/-
 bone marrow exhibited decreased 
arginase 1 expression by Northern blot and in situ 
hybridization following allergen challenge, compared to 
mice that received arginase 1
+/-
 bone marrow [140]. 
Additionally, the arginase 1-deficient chimeras did not 
exhibit significantly increased arginase activity following 
allergen challenge, indicating that bone marrow derived 
arginase 1 is the main contributor to increased arginase 
activity in experimental asthma [140]. In support, 
allergen-challenged arginase 2 knockout mice experience the 
same upregulation of lung arginase activity as wild type 
mice [140]. However, the ablation of arginase 1 from 
bone-marrow derived cells, or the complete knockout of 
arginase 2, did not affect basal nor allergen-induced 
inflammatory cell infiltration or differential counts in BAL 
[140]. These data suggest that arginase 2 and bone 
marrow-derived arginase 1 are not required for the 
development of lung inflammation in murine experimental 
asthma [140]. However, the results from the bone marrow 
cell derived arginase 1 deficient mice do not preclude the 
possibility that arginase 1 expressed in structural cells, such 
as the epithelial [43,99] or smooth muscle cells [39,43], may 
contribute to the development of allergic airways 
inflammation. The drastic reduction of arginase expression 
and activity did not induce an exacerbated inflammatory 
phenotype [140] as observed in the above-mentioned study 
using the arginase inhibitor BEC in mice [111].  
 By contrast, Pesce et al. recently generated arginase-1 
floxed transgenic mice crossed with two independent 
macrophage-specific cre-recombinase expressing strains, 
resulting in two strains of mice in which arginase 1 was 
conditionally knocked out in the macrophages [139]. Using a 
model of Schistosoma mansoni infection, which typically 
occurs through Th2 cytokines, these investigators 
demonstrated that deletion of arginase 1 actually augmented 
the hepatic fibrosis and granulomatous inflammation in 
diseased animals [139]. Thus, in this model, arginase 1 
expression in macrophages acts to suppress Th2-dependent 
fibrosis and inflammation [139]. 
 Taken together, the role of arginase in airway 
inflammation in experimental asthma is not completely 
understood as both anti-inflammatory and pro-inflammatory 
effects of arginase inhibition have been observed, whereas 
knockdown of arginase 1 in bone marrow derived cells or 
total knockdown of arginase 2 does not affect lung 
inflammation. Further studies, using conditional knockdown 
of arginase 1 in structural cells, will be key in understanding 
the complex role of altered L-arginine metabolism in allergic 
inflammation. While many interesting advances in our 
understanding of the apparently divergent roles of L-arginine 
metabolism in allergic inflammation have been made 
recently in animal models, we must consider how these 
mechanisms may be manifest in human asthma, and how 
they may potentially be modulated for future therapies.  
ARGINASE IN CHRONIC AIRWAY REMODELING 
 As previously described, chronic airway inflammation 
may induce airway remodeling. In particular, eosinophilia 
and secretion of TGF- and IL-13 are considered to play an 
important role [145]. However, Holgate et al. suggested an 
important interactive role for the structural cells of the 
airways in the remodeling process as put forward by in the 
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epithelial mesenchymal trophic unit hypothesis [146-148]. 
Recent advances also implicate arginase in airway 
remodeling, through the production of L-ornithine and 
subsequent synthesis of polyamines and L-proline (Fig 1). 
Polyamines promote cell growth and proliferation, while L-
proline is essential for collagen synthesis. 
 Lung fibrosis studies can also inform our understanding 
of the role of arginase in airway remodeling, as the 
mechanisms underlying increased collagen deposition in this 
disease likely exhibit some degree of overlap with those at 
work in asthma. Interestingly, the arginase activity in mouse 
lung tissue and fibroblasts was dose-dependently increased 
by the profibrotic factor TGF- [149]. Moreover, levels of 
TGF-, arginase activity and collagen content are all 
increased in rat lung allografts, with a strong correlation 
between arginase activity and collagen content [149]. 
Kitowska et al. recently explored the role of arginase in 
remodeling in lung fibrosis [150]. Increased expression of 
arginase 1, arginase 2 and collagen I, and a decrease in 
L-arginine availability, without alterations in protein arginine 
methyltransferases or CATs, were observed in mouse models 
of bleomycin-induced pulmonary fibrosis [101,151]. In 
addition, arginase 1 and 2 mRNA were induced by TGF-1 
in murine lung fibroblasts and inhibition of arginase by the 
nonspecific inhibitor NOHA attenuated TGF-1-stimulated 
collagen deposition in a post-transcriptional manner [101].  
 Another group studying lung fibrosis recently 
interrogated the genetic pathways upregulated by TGF-, 
using transgenic mice expressing human TGF-1 under the 
control of the Clara cell 10-kD (CC10) promoter [152]. After 
treatment with doxycycline, these animals displayed 
upregulation of IL-13, infiltration of alternatively-activated 
macrophages and increased pulmonary fibrosis [152]. 
Importantly, arginase 1 and 2 expression and total arginase 
activity in BAL were also upregulated in the transgenic mice 
at day 14 post TGF-1 induction [152]. These data support 
the hypothesis that arginase is induced by TGF- as part of a 
pro-fibrotic genetic program, likely contributing via the 
metabolism of L-arginine to L-ornithine, leading to increased 
downstream production of proline and polyamines. These 
studies together provide a functional link between TGF-1, 
arginase and collagen deposition in lung fibrosis. As 
TGF-1 is also known to contribute to lung remodeling in 
asthma [153,154], these studies provide strong support 
towards arginase playing a key role.  
 In murine models of allergic airways inflammation there 
have also been recent developments implicating arginase in 
airway remodeling. Recently, treatment of mice in an 
ovalbumin model of allergic inflammation with mepacrine, 
an antimalarial drug, was shown to reduce the levels of IL-4, 
IL-13 and TGF-1 as well as the expression and activity of 
arginases in the lung [155]. In this model, involving 
sensitization to ovalbumin on days 0, 7 and 14, followed by 
challenge with ovalbumin or vehicle beginning on day 21 for 
12 consecutive days, Masson trichrome staining revealed 
sub-epithelial fibrosis, which was also attenuated by 
treatment with mepacrine[155]. However, mepacrine is also 
known to reduce Th2 cytokines and cysteinyl leukotrienes 
[155], therefore this study does not provide specific evidence 
that reduced arginase is the sole factor contributing to the 
reduction of remodeling in this model. To date no data is 
available regarding arginase inhibition with a specific 
inhibitor in a chronic model of allergic airways 
inflammation, but this study provides some encouraging 
findings. However, a recent study indicates that arginase 2 
and bone marrow cell-derived arginase 1 are not important 
for allergen-induced fibrosis [140]. 
 Increased arginase activity could also play a role in lung 
fibrosis by decreasing the NO production, since NO is 
antifibrotic. The importance of NO in regulating lung 
collagen content was supported in a guinea pig model of 
ongoing asthma. Thus, the allergen-induced collagen 
deposition around non-cartilaginous airways [156], but not in 
the alveolar septa [157] was further increased by chronic 
treatment with the NOS inhibitor L-NAME. Moreover, 
increased deposition of collagen in the lung has been 
observed in allergen-challenged NOS2
-/-
 mice compared to 
allergen-challenged wild types [158].  
 Recently, novel studies have focused on the role of 
asymmetric dimethylarginine (ADMA) in respiratory 
function and disease. ADMA is an endogenous competitive 
inhibitor of NOS, derived from the breakdown of proteins 
containing L-arginine residues previously methylated by 
protein-arginine methyltranserases (PRMTs; Fig 1) 
[159,160]. The role of ADMA in the regulation of the 
L-arginine/NO pathway in vivo and airway remodeling is just 
beginning to be elucidated. Wells et al. infused saline or 
ADMA (30–90 mg/kg/day) via implanted osmotic 
minipumps in naïve Balb/c mice for 2 weeks [161]. 
Increased lung hydroxyproline content – as a marker for lung 
fibrosis - and collagen staining on histological sections were 
observed in ADMA-treated mice compared with saline-
treated controls with concomitant higher arginase activity, 
decreased nitrite concentrations and increased urea in lung 
homogenates [161]. Interestingly, ADMA treatment did not 
affect IL-13 or arginase expression [161]. Finally, it was 
shown that ADMA induced an increase in arginase activity 
and collagen fiber formation in primary mouse lung 
fibroblast cultures, and that this was preventable through 
addition of NOHA [161]. In addition, treatment with the 
NOS inhibitor L-NAME has been shown to further increase 
the IL-4-induced production of TGF- by lung fibroblasts 
[162]. 
 Another characteristic of airway remodeling is increased 
smooth muscle mass. In the vasculature, arginase has been 
shown to play a role in smooth muscle proliferation 
[163,164]. Elevated production of polyamines from L-
ornithine as well as decreased synthesis of NO due to 
increased arginase activity could therefore contribute to the 
process of airway smooth muscle thickening . The synthesis 
of the polyamines (putrescine, spermidine and spermine) is 
initiated by ornithine decarboxylase (ODC), which converts 
L-ornithine into putrescine [30]. Polyamines are involved in 
cell proliferation [3,30,55,80,165] and induce the expression 
of genes involved in cell proliferation by promoting histone 
acetyltransferase activity and chromatin hyperacetylation 
[166]. Studies in the vasculature have shown that the 
expression/activation of arginase and ODC can be induced 
by growth factors, leading to increased polyamine levels 
[167-171] and this activation of ODC has also been observed 
in the airway smooth muscle [172]. Importantly, levels of 
polyamines in lungs of allergen-challenged mice [99] and in 
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serum of asthmatic patients are increased [173]. The 
potential importance of arginase in this context is illustrated 
by the observation that arginase activity in the airways and 
lungs are increased in animal models of chronic allergic 
asthma [43,72]. 
 In contrast to polyamines, NO inhibits mitogen-induced 
proliferation of cultured airway smooth muscle cells from 
human [174-176] and guinea pig [177] origins, by inhibiting 
the G1 phase and the S phase of the cell cycle [175] This 
inhibitory effect of NO on airway smooth muscle 
proliferation is mediated by the activation of soluble 
guanylyl cyclase and subsequent cGMP production 
[174,175,177], but also involves cGMP-independent 
inhibition of ribonucleotide reductase [175]. The exact 
downstream mechanisms contributing to NO-mediated 
inhibition of airway smooth muscle cell proliferations are 
currently unknown, but studies in vascular smooth muscle 
cells have shown that NO represses cell cycle promoting 
genes and induces inhibitors of the cell cycle [178] and 
inhibits PDGF-induced activation of protein kinase B [179]. 
In addition, NO inhibits the activation of ODC via S-
nitrosylation of the enzyme under normal conditions [180].  
 Bergeron et al. examined L-arginine related proteins by 
immunostaining in asthmatic airways [39]. This study 
revealed increased arginase expression in asthmatics who 
smoke, localized to epithelia and the peri-bronchiolar region. 
This study suggests a role for arginase in injury and repair 
initiated by cigarette smoke insult [39]. It also demonstrates 
arginase expression in steroid-naïve asthmatics in anatomical 
proximity to remodeling features. 
 Conclusively, these findings suggest that increased 
arginase activity in chronic asthma could also contribute to 
the airway smooth muscle thickening via an increased 
production of polyamines from L-ornithine and via a reduced 
formation of NO. Studies using arginase inhibitors in animal 
models are warranted to elucidate the exact role of arginase 
in airway remodeling in chronic asthma. 
CELLULAR AND SUB-CELLULAR LOCALIZATION 
 A key level at which NOS and arginase can compete for 
substrate is through cellular and subcellular localization 
throughout the airways. Co-expression of arginase and NOS 
has been demonstrated in epithelial cells of the airways. The 
epithelial cells of the large airways are known to undergo 
significant changes in asthma, and their importance in AHR 
is beginning to be appreciated [181,182]. Damage and 
shedding of the epithelia has been observed in asthmatics 
and may contribute to the loss of bronchoprotection by 
cNOS-derived NO [88]. Increased arginase 1 has been 
shown in asthmatic airway epithelial cells in bronchoscopy 
samples [39,99]. Recent human data and murine models of 
allergic airways inflammation suggest expression in the 
apical layer of airway epithelial cells [43,150]. 
 Importantly, concomitant expression of NOS1 and 
arginase in airway epithelial cells supports the potential for 
arginase overexpression to reduce the local bioavailability of 
L-arginine for NOS1 in these cell types [102,111]. NOS1 has 
been demonstrated by ourselves and others to localize 
primarily to airway epithelial and smooth muscle cells 
[43,182]. As noted above, previous studies in guinea pigs 
have suggested that arginase activity can affect airway tone 
through increased competition with NOS1 in both 
homeostasis and under conditions of allergic inflammation 
[17,42,86,98]. Thus, arginase and NOS1 may be in 
competition for intracellular L-arginine pools within the 
same cells and under conditions of allergic inflammation this 
competition may be exacerbated by increased arginase 1 
expression.  
 In addition to whether or not specific cell types 
co-express the arginase/NOS isozymes, sub-cellular 
localization of L-arginine-related enzymes may be critical to 
understanding the outcome of dysregulation of proteins 
related to L-arginine metabolism. NOS1 contains a PDZ 
domain that participates in the formation of active dimers, 
and interactions with other proteins [183,184]. NOS1 has 
been localized to the cytosol, neuronal synapses and the 
plasma membrane [185,186]. In contrast, NOS2 has a 
relatively wide-ranging distribution in various cell types, 
including the cytosol, perinuclear space, plasma membrane 
and mitochondria [187-189]. NOS3 has been demonstrated 
at the plasma membrane, where it has complex intractions 
with caveolin and CAT1 [185,190-192]. Similar to NOS2, 
NOS3 has also been reported to be present in mitochondria 
[189]. Meanwhile, arginase 1 is localized primarily in the 
cytosol, while arginase 2 is confined to the mitochondria. 
Both arginase 1 and 2 have been implicated in regulating 
NOS1 activity through the depletion of intracellular 
L-arginine [193,194]. In cultured endothelial cells arginase 2 
has been demonstrated to regulate the activity of NOS3, and 
this regulation has been shown to take place within non-
freely exchangeable L-arginine pools [195,196]. 
Furthermore, over-expression of arginase 1 has been 
demonstrated to result in impaired NO production by NOS1 
in cultured 293 embryonic kidney cells stably transfected 
with NOS1 [194]. Ckless et al. investigated the colocalization 
of arginase 1 with NOS isoforms in C10 murine alveolar 
type II epithelial cells [144]. Through immunoprecipitation it 
was demonstrated that arginase 1 colocalized with NOS3, 
but not NOS1 or NOS2 in this cell type [144].  
 The subcellular localization of the arginase isoenzymes 
may also have implications in the downstream fates of the 
products of arginase and NOS, L-ornithine, and L-citrulline, 
respectively. The localization of ornithine decarboxylase 
(ODC) in the cytosol may preferentially steer cytosolic L-
ornithine towards the production of polyamines, which are 
important in cell proliferation. Ornithine amino transferase 
(OAT) is localized to the mitochondria, potentially directing 
the L-ornithine produced by arginase 2 towards the 
production of proline and collagen synthesis [197]. 
However, ,transport of L-ornithine across the mitochondrial 
membrane is known to occur [30]. Furthermore, recycling of 
L-citrulline to L-arginine by ASS and ASL may be important 
in regulating L-arginine availability for the NOS isoenzymes. 
ASS produces argininosuccinate from L-citrulline and 
aspartate as part of the L-citrulline-NO cycle, whereas ASL 
cleaves argininosuccinate into L-arginine and fumarate [30]. 
Both ASS and ASL are localized in the cytoplasm, indicating 
that the full recycling of L-citrulline to L-arginine may take 
place within that cellular compartment [198]. Future 
investigations of the role(s) of L-arginine-related 
proteins/pathways in the pathogenesis of disease will need to 
consider the potential impact of sub-cellular localization of 
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competing NOS and arginase isozymes and the pathways of 
downstream metabolism of their respective products. 
 In a recent paper examining the effectiveness of inhaled 
steroids on preventing remodeling, Kai et al. recently 
investigated collagen synthesis [199]. The authors measured 
sputum levels of procollagen type I C-terminal peptide 
(PICP), a marker of ongoing collagen synthesis, in 25 
normal volunteers and 25 steroid-naive asthmatics, who 
immediately began steroid treatment and were followed up 
one month later [199]. Asthmatics exhibited increased PICP, 
relative to controls, consistent with a previous study by the 
same authors. While treatment with inhaled corticosteroids 
improved the FEV1, and decreased sputum eosinophil 
counts, TGF-+ cells and sputum PICP concentrations, 
treatment did not normalize PICP concentrations to the level 
of controls, suggesting ongoing airway remodeling in 
steroid-treated asthmatics [200].  
 The effect of steroids on arginase expression in human 
asthma is currently unclear. There is some evidence that 
increased arginase expression can be induced by steroids, 
such as in the digestive tract of piglets treated with 
glucocorticoids [201]. Dexamethasone has also been found 
to increase arginase activity when administered to rescue 
mice from endotoxemia [202]. Whereas, in rat airway 
fibroblasts, dexamethasone has been reported to inhibit the 
IL-4/IL-13 induced upregulation of arginase [38]. However, 
dexamethasone was also reported to have no effect on 
endotoxin/TNF-induced upregulation of arginase in bovine 
pulmonary arterial endothelial cells [203]. More studies on 
the effects of corticosteroid treatment on arginase expression 
in asthma are needed, but a recent study by Lara et al., 
provides some information. In this study of severe 
asthmatics, moderate asthmatics and healthy controls, the 
severe asthmatics exhibited increased serum arginase activity, 
which was related inversely to airflow, despite the fact that 
95.2% of these patients were being treated with inhaled 
corticosteroids, and 38.1% with systemic corticosteriods 
[114]. Thus, there is significant potential for new therapies to 
target arginase, as current treatments do not appear to 
attenuate the activity of this pathway or prevent remodeling.  
FUTURE DIRECTIONS 
 Increased arginase activity importantly contributes to the 
development of key processes of allergic asthma, such as 
AHR, airway inflammation and – possibly – remodeling. 
Although some conflicting results have been reported, most 
studies investigating the effect in vivo inhibition of arginase 
demonstrate a beneficial effect of arginase inhibitors on 
AHR and airway inflammation. Therefore, arginase 
inhibitors may have therapeutic potential in the treatment of 
allergic asthma. Future experiments are warranted to 
elucidate the specific role the two arginase isozymes in 
disease pathogenesis and in homeostasis. To this aim, further 
investigation of new, more selective inhibitors and methods 
of administration that will minimize non-specific effects 
(i.e., inhibition of arginase in extrapulmonary tissues) as well 
as the use of conditional knockout animals are needed.  
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